Goodwill and Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments

The carrying values of goodwill assigned to the Company’s operating segments are as follows:

	Cell Therapy		Degenerative Disease			Biobanking		Total
Balance at December 31, 2019	$	112,347	$	7,374		$	7,347	$	127,068
Derecognition of goodwill related to sale of UltraMIST business		—		(3,764	)		—		(3,764	)
Impairment		—		—			—		—
Balance at December 31, 2020	$	112,347	$	3,610		$	7,347	$	123,304
Impairment		—		—			—		—
Balance at December 31, 2021	$	112,347	$	3,610		$	7,347	$	123,304

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

	December 31, 2021			December 31, 2020			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810			11 – 16 years
Customer relationships		2,413			2,413			10 years
Trade names & trademarks		570			570			10 – 13 years
Reacquired rights		4,200			4,200			6 years
		23,993			23,993
Less: Accumulated amortization
Developed technology		(5,376	)		(4,203	)
Customer relationships		(1,170	)		(906	)
Trade names & trademarks		(220	)		(165	)
Reacquired rights		(2,540	)		(1,840	)
		(9,306	)		(7,114	)
Amortizable intangible assets, net		14,687			16,879
Non-amortized intangible assets
Acquired IPR&D product rights		108,500			108,500			indefinite
	$	123,187		$	125,379

Schedule of Aggregate Amortization Expense Related to Intangible Assets

Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2021 is estimated as follows:

2022	$	2,193
2023		2,193
2024		1,784
2025		1,493
2026		1,356